// App-Quantinova.ai

2302 : An off the shelf, GMP-grade, IL-2-independent NK cell line expressing the high-affinity Fc-receptor to augment antibody therapeutics

Researchers

Presenter

  • Laurent Boissel

Principal Investigators

  • Hans Klingemann

  • Kerry Campbell

  • Karen Nichols

  • Frances Toneguzzo

  • Paula Marcus

  • Brent Williams

  • Armand Keating

  • Patrick Soon-Shiong

Medical Centers

  • NantKwest, Inc., Cambridge, MA

  • Fox Chase Cancer Center, Philadelphia, PA

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • NantKwest, Inc., Culver City, CA.

Locations

  • United States

  • Canada

Companies

  • Nantkwest Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Natural Killer cells

Drug/Treatment

  • Trastuzumab

  • Erbitux

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved